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A novel calcium-dependent serine proteinase (CASP) secreted from malignant hamster embryo fibroblast Ni 12C2 de- 
grades extraceUular matrix proteins. A complementary DNA encoding CASP has been isolated with the use of oligo- 
nucleotide probes synthesized based on partial amino acid sequences of CASP. The complete amino acid sequence of 
CASP revealed that it has a serine active site at the C-terminal side. Glu rich and proEGF homologous sites are found 
at the N-terminal site suggesting that it is structurally similar to blood coagulation factors such as IX, X and an anti- 
coagulation factor, protein C. 
Ca 2 +; Serine protease, Ca 2 +-dependent; cDNA; Protein, extracellular matrix 
1. INTRODUCTION 2. MATERIALS AND METHODS 
We have isolated a novel calcium-dependent 
serine proteinase [1] with a trypsin-type substrate 
specificity from the conditioned medium of 
hamster embryo fibroblasts Ni 12C2 cells which 
show high metastatic and phagocytotic activities 
[2,3]. Ca 2 +-dependent serine proteinase (CASP) 
degrades type I and IV collagen and fibronectin in 
the presence of calcium in the millimolar ange. 
For the hydrolysis of synthetic peptides acetyl Gly- 
L-Lys-naphthyl ester (AGLNE), however, CASP 
does not require calcium. The enzyme has been 
shown to be an 88 kDa heterodimer, consisting of 
heavy (66 kDa) and light (33 kDa) chains with 
disulfide bond(s) [1]. In the present study, we have 
cloned CASP cDNA and determined the complete 
primary structure of the CASP. 
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2.1. Cell culture 
Ni 12C2 hamster fibroblasts were cultured in Eagle's minimal 
essential medium supplemented with 10% newborn calf serum 
on plastic tissue culture dishes. 
2.2. Protein sequence analysis 
CASP was purified from the conditioned medium of Ni 12C2 
hamster fibroblasts as described [1]. The heavy and light chains 
of CASP were eluted from the SDS-polyacrylamide gel. 
N-terminal amino acid sequences of both chains have been 
determined using a model 470A gas phase sequencer (Applied 
Biosystems). The sequences thus obtained were EPTMHX- 
EILSPNYPQAYPNEMEXXXXIXV (X denotes undetermined 
amino acid) and FXXFPAKIQSFPXQVFFEFPXAXXALI for 
heavy and light chains, respectively. 
2.3. Oligonucleotide synthesis 
Oligonucleotides based on the N-terminal amino acid se- 
quences of both heavy and light chains were synthesized ac- 
cording to the most frequent codon usage in rat ot and ff actin 
genes [4]. (A) CTCCATCTCGTTGGGGTAGGCCTGGGGG- 
TAGTTGGGGGACAGGATCTC for heavy chain and (B) 
GGGGAACTCGAAGAACACCTGGGCGGGGAAGGACT- 
GGATCTTGGCGGGGAA for light chain were synthesized 
with an automatic DNA synthesizer (Applied Biosystems). 
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2.4. Construction of  Agt 10 cDNA library 
A cDNA library of 1.0 × 10 7 independent clones was 
prepared from total poly(A) + RNA of Ni 12C2 with the use of 
Agtl0 vector system as described [5]. 
2.5. Isolation of  CASP cDNA clones 
About 4 × 105 phages were screened for CASP cDNA clone 
by hybridization analysis using 5'-end labeled oligonucleotide 
probes A and B. The hybridization was Carried out in 40°70 for- 
mamide-5 x SSPE (1 × SSPE is 0.18M NaC1-0.01 M 
sodium phosphate-10 mM EDTA-5 x Denhardt's solu- 
tion-0.1 070 SDS-100/~g/ml salmon sperm DNAfor 16 h at 42°C 
and the nylon filter (Pall) was washed with 6 × SSC-0.1 070 SDS 
at room temperature. Plaques that gave positive signals were 
purified by a secondary plating and rescreening. Only probe A 
gave a positive signal under the present condition. A positive 
clone was isolated and subsequently subcloned into pTZ18R 
(Pharmacia) (pHCSP). 
2.6. Nucleotide sequence analysis 
The DNA sequence was determined by the dideoxy method 
using progressive deletion of the plasmid with exolII (USB). A 
search for homology of CASP sequence with known amino acid 
sequences was carried out using the GenBank/NBRS data 
library. 
3. RESULTS AND DISCUSSION 
Using probe A, we have isolated cDNA clone for 
CASP.  From the nucleotide sequence, the primary 
structure for CASP was determined. Complete se- 
quence analysis revealed the presence of  an open 
reading frame of  695 amino acids and the poly(A) 
tract (18 base pairs) (fig. 1). The potential initiation 
codon ATG which conforms to Kozak's criteria [6] 
is at 281 nucleotide followed by a typical signal 
peptide sequence of  21 amino acids. Experimental- 
ly determined N-terminal sequences of  the heavy 
and light chains were completely identical to those 
derived from the nucleotide sequences (amino acid 
22-50 and 446-472 residues, respectively). Heavy 
and light chains, therefore, are tandemly located in 
this order. RNA blot hybridization analysis reveal- 
ed that the size of  the mRNA of  CASP is 3.0 kb 
(not shown) indicating that CASP is derived from 
a single transcript and that the isolated cDNA 
covers a nearly full-length region of  the mRNA.  
Thus, two chains encoded by a single gene might 
arise through proteolytic cleavage of  the single 
polypeptide chain. The cleavage site is thought to 
be between Arg (444) and Ile (445) (fig. 1) based on 
the experimentally determined N-terminal amino 
acid sequence of  the light chain. The same sequence 
(Arg-Ile) is also cleaved in the case of  chymotryp- 
sinogen [7] (fig.2B). Two possible N-glycosylation 
sites are found in the heavy chain but not in the 
light chain. The heavy chain indeed has N-linked 
oligosaccharide(s) ince the treatment of  CASP 
with endoglycosidase F resulted in the reduction of  
the molecular mass of  the heavy chain but not the 
light chain (Sakiyama et al., in preparation). The 
overall structure of  CASP is schematically shown 
in fig.2A. 
All members of  the serine proteases share strong- 
ly conserved amino acid sequence blocks that make 
up the active site of  the enzyme. This sequence 
(amino acid residues 633-640) is also highly con- 
served in CASP.  By comparing the amino acid se- 
quence of CASP with that of  chymotrypsinogen 
with which CASP shares 33.6070 homology,  we 
predict the three reactive residues of  this enzyme to 
lie at positions 482(His), 536(Asp) and 638(Ser) 
(fig.l). The consensus of  the amino acids surroun- 
ding these active residues is also seen (fig.2B). The 
light chain of  CASP shares a high homology with 
protein C (34o7o) whose homologous sites, like 
chymotrypsinogen, are centralized around the 
regions of  active site residues of  serine proteases. 
The catalytic site of  CASP,  therefore, is thought o 
be the light chain. The overall homology of  the 
amino acid sequence between the light chain and 
serine proteases was between 22°7o and 40°7o. 
The heavy chain which we consider to be a 
regulatory subunit contains Glu-rich region (15 of  
103 amino acid residues) at the N-terminal part 
(positions 22-124) followed by a proEGF 
homologous domain (positions 137-177). An align- 
ment of  amino acid residues of  the domains of  the 
proteases homologous to proEGF is shown in 
Fig. 1. Nucleotide sequence of CASP cDNA and translated amino acid sequence of CASP. (A) Restriction map of CASP cDNA. The 
solid region is a open reading frame. (B) The 2085-nucleotide open reading frame is flanked by 3'-untranslated sequences of 364 
nucleotides containing a polyadenylation signal, AATAAA (overlined) and a poly(A) tail, and by the 5'-untranslated region of 280 
nucleotides. ~ ,  signal peptide; .... , EGF precursor-like r gion; : v, a possible cleavage site between heavy and light chains; % sites 
of possible asparagine-linked glycosylation; • ,  His, Asp and Ser which are the active sites of serine protease are indicated. N-terminal 
amino acid sequence ofheavy chain determined using a gas phase sequencer is underlined, and that of light chain is wavy-underlined. 
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Fig.2. (A) The overall structure of CASP precursor p otein. Sites of possible asparagine-linked glycosylation are indicated by 
rhombuses. (B) Comparison with junctional nd catalytic regions of chymotrypsinogen. (C) Comparison with epidermal growth factor- 
like region and protein Cprecursor. :, identical residues; A, cleavage site ; •, His, Asp and Ser active site residues of serine proteases; 
-, gaps inserted to maximize sequence identity; numbers inparentheses are the region of amino acid sequences shown. 
fig.2C. The sequence of CASP, as protein C, has 
the arrangement of cysteine residues characteristic 
of proEGF domain. This domian comprises Asp 
whose ~'-hydroxylation can be correlated with Ca 2÷ 
binding [8]. Although it is still under investigation, 
Glu in the N-terminal region may be 7- 
carboxylated and function as a Ca 2÷ binding site 
[9]. If that is the case, CASP binds with Ca 2÷ 
through 7-carboxyglutamic acid (Gla) and #- 
hydroxyaspartate via a mechanism similar to that 
of blood coagulation factors such as IX, X and 
protein C [10,11]. When the Ca 2+ binding 
regulatory domains of coagulation factors are 
removed, they are activated as serine proteinases. 
CASP, however, is secreted as an active form since 
it degrades (AGLNE) without any cleavage of the 
enzyme. The addition of Ca 2÷ induces autodiges- 
tion. It is possible that the self-digestion of the 
regulatory domain of the enzyme is required to 
potentiate the enzyme to degrade native proteins. 
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